Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MZT Holdings Inc.

Division of Abbott Laboratories Inc.
www.matritech.com

Latest From MZT Holdings Inc.

Prostate Cancer Market: $2 Billion and Growing

Although prostate problems have plagued men for many years, the growing elderly population is now driving an unprecedented increase in caseloads and a corresponding need for improved treatments. One of the primary concerns is the rise in prostate cancer diagnoses. With more than two million American men currently living with prostate cancer and more than 200,000 new cases diagnosed each year, the market for diagnostic and therapeutic products to address this disease is substantial; more than $2 billion in the US in 2007.
Medical Device

Medical Device and In Vitro Diagnostics Deal Statistics Quarterly, Q3 2007

In this issue, we present another installment of our quarterly review of medical device and in vitro diagnostics/research dealmaking-for July-September 2007. Our data are derived from Windhover's Strategic Transactions Database.
BioPharmaceutical Medical Device

The Search for Prostate-Specific Answers

Diseases of the prostate constitute the second most prevalent type of chronic disease in the male population in the US. The recent report "US Markets for Diagnostic and Therapeutic Prostate Disease/Disorder Management Products," a report published in August 2007 by the Medtech Insight division of Windhover Information, details the state-of-the industry for companies working in benign prostatic hyperplasia, prostate cancer, and prostatitis. A brief excerpt on biomarkers for prostate cancer appears here.
BioPharmaceutical Medical Device

With Pluck and Luck, Sysmex Tackles Hematology

Sysmex's break in the US with distribution partner Roche frees it to reap the rewards of building its own brand. It's betting that a best-of-breed strategy can help it double revenues by 2006 and increase margins. It's got a stellar reputation but it's in a tough market that doesn't leave much room for error.
Medical Device North America
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
    • Molecular Diagnostics & Genetic Testing
    • Urine-based Testing
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Alias(es)
  • Matritech Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Abbott Laboratories Inc.
  • Senior Management
  • Stephen D Chubb, Chmn. & CEO
    Richard S Sandberg, VP, Fin. & CFO
    David Corbet, Pres. & COO
    David G Kolasinski, VP, Sales
    Gary Fagan, PhD, VP, R&D
  • Contact Info
  • MZT Holdings Inc.
    Phone: (617) 928-0820
    330 Nevada St.
    Newton, MA 02460
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register